SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Group 1: Fellowship Announcement - The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology announced the second annual CG-SUO-CTC NMIBC Research Fellowship to support clinical cancer research focused on Non-Muscle Invasive Bladder Cancer (NMIBC) [2][4] - Two applicants will each receive a grant of $50,000 to support their research projects, with applications due by February 27, 2026 [1][4] Group 2: Research and Innovation - There is a significant unmet need for treating NMIBC, and the fellowship aims to advance research and innovation in this area, improving patient care [3] - The program provides an opportunity for emerging urologists to collaborate with mentors and present their findings at prominent forums such as the American Urological Association (AUA) annual meeting [3][4] Group 3: Bladder Cancer Statistics - In 2024, more than 83,000 people are estimated to be diagnosed with bladder cancer, with NMIBC representing approximately 75% of newly diagnosed cases [5] - Bladder cancer is the sixth most common form of cancer in the United States, with men accounting for three-quarters of new diagnoses [5] Group 4: Organizations Overview - SUO-CTC is a clinical research network with over 600 members from more than 300 clinical sites in the U.S. and Canada, dedicated to advancing urology research [6] - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer patients [7]